Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Cempra Inc. , of Chapel Hill, N.C., presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin vs. levofloxacin i ...

BioWorld Today - Staff - 2013-05-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Asahi Kasei Pharma America Corp. , of Waltham, Mass., said it started an 800-patient Phase III trial of ART-123 (recombinant human thrombomodulin, sold as Recomodulin in Japan) in severe sepsis patients with coagulopathy. (BioWorld-T ...

BioWorld Today - Staff - 2012-11-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• A.P. Pharma Inc. , of Redwood City, Calif., reported additional data from a Phase III trial of APF530, for chemotherapy-induced nausea and vomiting. (BioWorld-Today-2012-07-02) ...

BioWorld Today - Staff - 2012-07-02 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Galleon Pharmaceuticals Inc. , of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, w ...

BioWorld Today - Staff - 2012-05-08 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Avillion Group , of London, said it entered an exclusive collaborative development agreement with Pfizer Inc. , of New York, to conduct a Phase III trial of Bosulif (bosutinib). (BioWorld-Today-2014-01-10) ...

BioWorld Today - Staff - 2014-01-10 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Astrazeneca plc , of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significa ...

BioWorld Today - Staff - 2014-05-14 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported results from two phase II studies of bivalent rLP2086, its recombinant vaccine candidate in development for the prevention of invasive meningococcal disease caused by Neisseria meningitides serogroup B in subje ...

BioWorld Today - Staff - 2014-05-12 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Dompe Group , of Milan, reported preliminary phase I results confirming the tolerability of its recombinant human nerve growth factor (rhNGF), in development for ophthalmic use as a treatment for neurotrophic keratitis. (BioWorld-Today-2014- ...

BioWorld Today - Staff - 2014-05-09 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Novartis AG , of Basel, Switzerland, presented results at the European Congress of Endocrinology in Wroclaw, Poland, from a pivotal phase III study of Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of c ...

BioWorld Today - Staff - 2014-05-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

UCB SA , of Brussels, Belgium, reported results from the PRECiSE 3 seven-year open-label extension trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. (Bi ...

BioWorld Today - Staff - 2014-05-06 00:00 - 0 comments - 0 attachments